Alvotech (ALVO) said Thursday it is acquiring Xbrane Biopharma's R&D operations and biosimilar candidate XB003 for about 275 million Swedish krona ($27.2 million).
The acquisition, which is expected to close in April, includes Xbrane's R&D operations in Campus Solna, Sweden. Xbrane will retain other pre-clinical assets.
Alvotech also said it plans to explore a potential listing of Swedish depository receipts on Nasdaq Stockholm in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.